STOCK TITAN

Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Agile Therapeutics, Inc. (AGRX) will report its fourth quarter and full year 2023 financial results on March 28, 2024. A live conference call and webcast will follow to discuss the financial results and provide a business update.
Positive
  • None.
Negative
  • None.

Live Conference Call and Webcast at 8:30 a.m. ET

PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update.

EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference Call
DateThursday, March 28, 2024
Time8:30 a.m. ET / 5:30 a.m. PT


A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.

About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website and LinkedIn account.

Contact:
Matt Riley

Head of Investor Relations & Corporate Communications

mriley@agiletherapeutics.com


Agile Therapeutics (AGRX) will report its fourth quarter and full year 2023 financial results on Thursday, March 28, 2024.

The live conference call and webcast to discuss Agile Therapeutics' (AGRX) financial results will be held at 8:30 a.m. ET on Thursday, March 28, 2024.

The live webcast of Agile Therapeutics' (AGRX) conference call can be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations.

To participate in the live conference call via telephone to discuss Agile Therapeutics' (AGRX) financial results, please register at the provided link. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.
Agile Therapeutics Inc

NASDAQ:AGRX

AGRX Rankings

AGRX Latest News

AGRX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Princeton

About AGRX

agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.